Clinical Research
EMSCO provides services including review of trial design, medical writing, support with essential clinical trial documents, contracts, publications, management and coordination of clinical trials and other projects associated with MDS. EMSCO’s multilingual staff has ample experience in the international context and is therefore apt to fulfil these tasks.
One of the major goals of EMSCO is to offer an expert MDS office team to assist, design and review clinical trials in MDS. The group offers full-service Sponsor responsibilities across Europe with KOLs in the participating countries to take over CPI roles and experienced staff for comprehensive trial management tasks. Within this environment we aim to improve the quality and comparability of clinical trials in MDS.
EMSCO trials
| Recruitment ongoing | |
|---|---|
| REMARK TRIAL (NCT06243458) | A Phase II, Open-label, Multicenter Study of Orally Administered RVU120 for the Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms (MDS) Status: recruiting in Germany, France, Italy, Spain, Poland |
| IMPRESS TRIAL (NCT05583552) | A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy |
| LUSPLUS TRIAL (NCT05181592) | A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS) Status: recruiting in Germany |
| LENNON TRIAL (NCT05384691) | A Phase II, Open-label, Single Arm Study to Evaluate the Efficacy of Luspatercept in Erythropoiesis-stimulating Agent Naive Lower-risk MDS Patients With or Without Ring Sideroblasts Who do Not Require RBC Transfusions |
| Recruitment completed / finished trials | |
| LUCAS TRIAL (NCT05178342) | Treatment of Anemia in patients with very low, low or intermediate risk myelodysplastic syndromes with CA-4948 Status: recruitement completed (prematurely terminated) |
| IDEAL TRIAL (NCT03744390) | A single-arm phase II multicenter study of IDH2 (AG-221) inhibitor in patients with IDH2-mutated MDS Status: recruitment completed |
| PALOMA TRIAL (NCT04061239) | Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML Status: recruitement completed |
| IDIOME TRIAL (NCT03503409) | A single-arm phase II multicenter study of IDH1 (AG 120) inhibitor in patients with IDH1 mutated myelodysplastic syndrome Status: trial completed |
| CANFIRE TRIAL (NCT05237713) | A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS) Status: recruitement completed (prematurely terminated) |
| DACOTA TRIAL (NCT02214407) | Randomized Phase III study of decitabine (DAC) with or without hydroxyurea (HY) versus HY in patients with advanced proliferative Chronic Myelomonocytic Leukemia (CMML) Status: trial completed |
| SAMBA TRIAL (NCT02992860) | Single agent JNJ-56022473 in MDS and AML patients failing hypomethylating agent based therapy Status: trial completed (prematurely terminated) |
| BERGAMO TRIAL (NCT03824080) | A phase II study evaluating the efficacy and safety of bemcentinib in patients with MDS or AML failing standard of care therapy Status: trial completed |
| EUROPE TRIAL (NCT02335268) | Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia Status: trial completed |
| SINTRA-REV TRIAL (NCT01243476) | Multicenter, randomized, double-blind, phase III study of Revlimid® (lenalidomide) versus placebo in patients with low risk myelodysplastic syndrome (low and intermediate-1 IPSS) with alteration in 5q and anemia without the need of transfusion Status: trial completed |